In this Healio Video Perspective from Retina 2025, Ashkan M. Abbey, MD, discusses 1-year results from the phase 2 DAVIO 2 clinical trial investigating EYP-1901 in previously treated wet age-related ...

HC Wainwright reissued their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) in a report released on Tuesday morning,Benzinga reports. The firm currently has a ...

Outlook Therapeutics, Inc. (NASDAQ:OTLK – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat reports ...

NIH’s plan to cut what it pays universities and other entities for indirect costs associated with scientific research would create “extremely challenging” short- and long-term impacts, according to a ...

A study found that injecting mesenchymal stem cells into periocular tissue effectively reduces eye inflammation without ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...

There is currently no cure for dementia. However, there are treatments and support services that can help someone with the condition. These include drug and non-drug treatments, support, activities, ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Two new medications, called lecanemab and donanemab, have shown success in clinical trials in slowing down Alzheimer’s disease. These are known as disease-modifying treatments and have been licensed ...

Our picks of the movies you need to be watching on Netflix in February.